Mammalian cell lines, viral vectors, and transgenic mice
control mechanism
Doxycycline allosteric modulation of fused E. coli TetR and herpesvirus VP16 transactivators (tTA / rtTA)
pioneer
Manfred Gossen and Hermann Bujard (University of Heidelberg, Tet-Off published 1992)
Core Principles & Analysis
Developed by Hermann Bujard and Manfred Gossen at the University of Heidelberg and published in 1992, the tetracycline transactivator (tTA) fuses the Escherichia coli TetR repressor to the herpes simplex virus VP16 transcriptional activation domain.
In the Tet-Off system, tTA binds tetracycline-response element (TRE) promoters to drive transcription only in the absence of doxycycline, whereas in the Tet-On system, reverse tTA (rtTA) binds DNA and activates transcription only when doxycycline is present.
Engineered variants such as Tet-On Advanced (rtTA2S-M2, discovered in 2000) and Tet-On 3G (rtTA-V10) incorporate human codon optimization and mutated TetR domains that lower background leakiness and increase doxycycline sensitivity up to 100-fold.